The stock of Acasti Pharma Inc (CVE:ACST) hit a new 52-week high and has $2.64 target or 6.00% above today’s $2.49 share price. The 5 months bullish chart indicates low risk for the $29.58 million company. The 1-year high was reported on Nov, 29 by Barchart.com. If the $2.64 price target is reached, the company will be worth $1.77M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 19,860 shares traded hands or 940.34% up from the average. Acasti Pharma Inc (CVE:ACST) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.
More recent Acasti Pharma Inc (CVE:ACST) news were published by: Marketwatch.com which released: “Acasti Pharma Inc.” on November 28, 2016. Also Quotes.Wsj.com published the news titled: “News Acasti Pharma Inc.ACST” on January 08, 2013. 247Wallst.com‘s news article titled: “Acasti Pharma Share Gains Massive in Percentage Terms, Tiny in Dollars” with publication date: September 14, 2016 was also an interesting one.
Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $29.58 million. The Firm is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. It currently has negative earnings. The Firm is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.